| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5050f8a78737ea730347d5e3d039fd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3beb0bf66d7c1c7976c556d2c4684ac8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-575 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67300538cdf8044545fa2fdec968ae0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c9897f07b658bfee40199bf983cb660
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_002953c533e844064d76a15279b426ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4129d4c56c2813fcedb121d6f87b540
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f1649ab183bb2965649cf510aecc92d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fd7df1793cc708876ed58a2ab3f5ffa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd7c666d5bf2ac9f4b6c4d676c12d83a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188a89d93e9112e61bd5849fcb25887f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_687dffaaf3e1af485aab171071e1813a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0aa9c5f7ebf7b1828d6a6b9d685db26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68010bc06befb2940d7437b2d8752cb9 |
| publicationDate |
2019-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3557258-A1 |
| titleOfInvention |
Use of in1-ghrelin for the diagnosis of prostate cancer |
| abstract |
The present invention relates to a diagnostic and/or prognostic method for the diagnosis and/or prognosis of cancer in a patient. Particularly, the present invention relates to diagnostic and/or prognostic methods for the diagnosis and/or prognosis of cancer which comprise quantifying the expression levels of In1-ghrelin in a plasma sample isolated from an individual; comparing the obtained levels with the expression levels of In1-ghrelin in a reference sample; and assigning the patients having expression levels of In1-ghrelin that are greater than and statistically significant with respect to the levels of the reference sample to the group of individuals at risk of having cancer. The present invention also provides a diagnostic method for the diagnosis of bladder and/or colon cancer which comprises quantifying the expression levels of In1-ghrelin, GOAT and/or GHS-Rlb in tissue samples. The present invention also relates to an siRNA useful in a cancer treatment method. |
| priorityDate |
2016-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |